Alto Neuroscience, Inc. (ANRO)
| Market Cap | 895.50M +441.3% |
| Revenue (ttm) | n/a |
| Net Income | -84.24M |
| EPS | -2.38 |
| Shares Out | 39.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 681,860 |
| Open | 22.36 |
| Previous Close | 21.94 |
| Day's Range | 22.01 - 23.40 |
| 52-Week Range | 6.72 - 37.48 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 38.38 (+68.19%) |
| Est. Earnings | Nov 11, 2026 |
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 pro... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price target is $38.38, which is an increase of 68.19% from the latest price.
News
Alto Neuroscience price target raised to $60 from $55 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Alto Neuroscience (ANRO) to $60 from $55 and keeps a Buy rating on the shares. The company has three Phase 2b readouts…
Alto Neuroscience Slides: Investor presentation
Alto Neuroscience has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
Alto Neuroscience Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
ALTO-207's phase II-B trial for TRD is progressing, leveraging a novel combination to improve tolerability and efficacy, with top-line data expected next year. Broader pipeline programs, ALTO-300 and ALTO-100, are also advancing, targeting MDD and bipolar depression with innovative approaches.
Alto Neuroscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The conference highlighted a robust late-stage pipeline focused on precision psychiatry, with ALTO-207 leading a three-trial program in treatment-resistant depression and phase II-B data expected in H2 2027. ALTO-300 and ALTO-100 are advancing with biomarker-driven and novel mechanisms, while operational improvements have enhanced trial quality.
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience names Nick Smith president, CFO
Alto Neuroscience (ANRO) announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Smith will continue to lead Alto’s finance function and oversee corp...
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disord...
Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Alto Neuroscience (ANRO) to $55 from $50 and keeps a Buy rating on the shares following the Q2 report. The company expanded…
Alto Neuroscience reports Q EPS (65c), consensus (77c)
“The second quarter further strengthened the case for ALTO-207 and our conviction in the opportunity ahead of it,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto…
Alto Neuroscience price target raised to $37 from $28 at BTIG
BTIG analyst Thomas Shrader raised the firm’s price target on Alto Neuroscience (ANRO) to $37 from $28 and keeps a Buy rating on the shares. Modest update as the ALTO-207…
Alto Neuroscience price target raised to $37 from $33 at BofA
BofA raised the firm’s price target on Alto Neuroscience (ANRO) to $37 from $33 and keeps a Buy rating on the shares after the company reported Q2 results and updates…
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience Earnings release: Q2 2026
Alto Neuroscience released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Alto Neuroscience Quarterly report: Q2 2026
Alto Neuroscience has published its Q2 2026 quarterly earnings report on August 12, 2026.
Alto Neuroscience Slides: Corporate presentation
Alto Neuroscience has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering
Alto Neuroscience (ANRO) announced the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares…
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neu...
Alto Neuroscience Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The summit highlighted advances in precision psychiatry using EEG biomarkers to guide drug development for neuropsychiatric disorders. Key programs, including ALTO-207 for TRD, are progressing through late-stage trials with major data readouts and regulatory milestones expected by 2027.
Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol
Alto Neuroscience (ANRO) highlighted the publication in Nature Medicine of Prime-Praxol, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patie...
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, d...
Alto Neuroscience Slides: Corporate presentation
Alto Neuroscience has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Alto Neuroscience Transcript: Jefferies Global Healthcare Conference 2026
Precision psychiatry pipeline advances with ALTO-207, ALTO-300, and ALTO-100, each targeting major unmet needs in depression and bipolar disorder. Phase II-B and III trials are underway, with rigorous patient selection and strong financial runway through 2029.
Alto Neuroscience appoints Miller to Board of Directors
Alto Neuroscience (ANRO) announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. Most recently, Miller was the Founder and President of R&D at…
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience price target lowered to $33 from $35 at BofA
BofA analyst Tazeen Ahmad lowered the firm’s price target on Alto Neuroscience (ANRO) to $33 from $35 and keeps a Buy rating on the shares. The firm updated its model…